Electra Therapeutics (NASDAQ:ETRA) Director Purchases $164,800.00 in Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Carl Gordon acquired 20,000 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were acquired at an average cost of $8.24 per share, with a total value of $164,800.00. Following the completion of the transaction, the director directly owned 5,234,578 shares in the company, valued at approximately $43,132,922.72. The trade was a 0.38% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Electra Therapeutics Stock Performance

Shares of ETRA opened at $9.11 on Friday. Electra Therapeutics, Inc. has a 12-month low of $6.86 and a 12-month high of $15.50.

Electra Therapeutics (NASDAQ:ETRA) last announced its earnings results on Thursday, November 12th. The company reported ($3.47) earnings per share for the quarter, missing the consensus estimate of ($1.76) by ($1.71). On average, equities analysts anticipate that Electra Therapeutics, Inc. will post -3.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ETRA shares. Zacks Research raised shares of Electra Therapeutics to a “hold” rating in a research note on Wednesday, October 14th. Cantor Fitzgerald assumed coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued an “overweight” rating for the company. TD Cowen began coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They issued a “buy” rating on the stock. HC Wainwright started coverage on Electra Therapeutics in a research note on Monday, October 26th. They set a “buy” rating and a $30.00 price target on the stock. Finally, JPMorgan Chase & Co. started coverage on Electra Therapeutics in a research note on Thursday, October 22nd. They set an “overweight” rating and a $36.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Electra Therapeutics presently has a consensus rating of “Buy” and an average target price of $33.50.

About Electra Therapeutics

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.